Imatinib 40-mg/mL Oral Suspension

Author(s):  Allen Loyd V Jr

Issue:  Nov/Dec 2016 - Volume 20, Number 6
View All Articles in Issue

Abstract:  A formulation for preparing Imatinib 40-mg/mL Oral Suspension. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords: imatninib, formulation, hazardous medication, antineoplastic agent, cancer, leukemia, gastrointestinal stromal tumor, GIST, protein tyrosine kinase inhibitor, BCR-ABL inhibitor, receptor tyrosine kinase inhibitor, platelet-derived growth factor receptor, PDGF, PDGFR, stem cell factor inhibitor, SCF, c-kit inhibitor

Related Categories: CANCER AND AIDS, FORMULATIONS, HAZARDOUS DRUGS

Purchase this article for download in electronic PDF format from IJPC at for $75 at:
https://ijpc.com/Abstracts/Abstract.cfm?ABS=4249

Search the entire IJPC archive by keyword, topic, or issue at:
https://ijpc.com/Products